Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rami Komrokji

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2023
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib StudyDavid A Sallman, Monzr M Al Malki, Adam S Asch, et al.
Thrombosis Journal|July 16, 2019
Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experienceAbu-Sayeef Mirza, Seongseok Yun, Najla Al Ali, et al.
Haematologica|May 7, 2026
Myelodysplastic syndrome with concomitant <i>SF3B1</i> mutation and deletion of chromosome 5 long arm: outcomes and response to treatmentRami Komrokji, Zaker Schwabkey, Zena Komrokji, et al.
Hemasphere|May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with MyelofibrosisJohn Mascarenhas, Anna Rita Migliaccio, Heidi Kosiorek, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating AgentsSophie Park, Jean-François Hamel, Andrea Toma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Caterina Gregorio, Marie Robin, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2023
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib StudyDavid A Sallman, Monzr M Al Malki, Adam S Asch, et al.
Thrombosis Journal|July 16, 2019
Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experienceAbu-Sayeef Mirza, Seongseok Yun, Najla Al Ali, et al.
Haematologica|May 7, 2026
Myelodysplastic syndrome with concomitant <i>SF3B1</i> mutation and deletion of chromosome 5 long arm: outcomes and response to treatmentRami Komrokji, Zaker Schwabkey, Zena Komrokji, et al.
Hemasphere|May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with MyelofibrosisJohn Mascarenhas, Anna Rita Migliaccio, Heidi Kosiorek, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating AgentsSophie Park, Jean-François Hamel, Andrea Toma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Caterina Gregorio, Marie Robin, et al.
Pageof 13